Midodrine: Drug Class, Mechanism of Action, and Clinical Uses
Midodrine is an oral alpha-1 adrenergic agonist prodrug indicated for symptomatic orthostatic hypotension, working through peripheral vasoconstriction to increase blood pressure without cardiac stimulation. 1
Drug Class
Midodrine is a selective peripheral alpha-1 adrenergic agonist that acts as a prodrug 1.
Mechanism of Action
After oral administration, midodrine undergoes enzymatic hydrolysis in multiple tissues to form its active metabolite, desglymidodrine 1. This metabolite:
- Activates alpha-1 adrenergic receptors on arteriolar and venous vasculature
- Increases vascular tone through vasoconstriction of both arterioles and venous capacitance vessels
- Elevates blood pressure by increasing peripheral vascular resistance and augmenting venous return
- Does NOT stimulate cardiac beta-adrenergic receptors, avoiding cardiac stimulation 1
- Poorly crosses the blood-brain barrier, minimizing central nervous system effects 1
The pharmacokinetics show midodrine peaks in plasma at 30 minutes with a half-life of 25 minutes, while desglymidodrine reaches peak concentrations at 1-2 hours with a 3-4 hour half-life 1. The bioavailability is 93% and is not affected by food 1.
Clinical Uses
FDA-Approved Indication
Symptomatic orthostatic hypotension - specifically for patients whose lives are considerably impaired despite standard non-pharmacologic care (support stockings, fluid expansion, lifestyle modifications) 1. The indication is based on midodrine's effect on increasing 1-minute standing systolic blood pressure by approximately 15-30 mmHg at 1 hour after a 10 mg dose 1.
Guideline-Supported Use
Midodrine can be beneficial in patients with syncope due to neurogenic orthostatic hypotension 2. The 2017 ACC/AHA/HRS syncope guidelines note it improves symptoms of orthostatic hypotension with a dose-dependent effect corresponding to increased standing blood pressure 2.
Evolving Off-Label Uses
While not FDA-approved, midodrine has been explored for:
- Intradialytic hypotension in end-stage renal disease
- Hepatorenal syndrome (though evidence is limited and conflicting)
- Facilitating vasopressor weaning in shock states
- Potentially enabling guideline-directed medical therapy in heart failure (though this remains controversial with safety concerns) 3, 4, 5
Dosing and Administration
Typical dosing is 2.5-10 mg three times daily, with the last dose taken at least 4 hours before bedtime to minimize supine hypertension risk 2, 1. The effect persists for 2-3 hours after dosing 1.
Important Adverse Effects and Limitations
Common side effects directly related to alpha-agonism include 2, 1:
- Scalp tingling and piloerection
- Urinary retention
- Supine hypertension (can exceed 200 mmHg systolic - this is the most significant limiting factor)
- Pruritus and paresthesias
Critical caveat: Midodrine should only be continued in patients who report significant symptomatic improvement 1. The risk of supine hypertension necessitates avoiding late evening doses and careful blood pressure monitoring 2.